Respuesta completa patológica en cáncer de colon metastásico tratado con quimioterapia y bevacizumab. A propósito de un caso

Tabla 1. Grados de respuesta completa patológica por diferentes autores

Anexo – cáncer de colon en tratamiento con quimioterapia y bevacizumab 

TRG: grado de regresión del tumor

MjHR respuesta tumoral mayor histológica

PHR respuesta tumoral parcial histológica

NHR no respuesta tumoral histológica

PRG grado de respuesta patológica

BIBLIOGRAFÍA:

1. Blazer D, Kishi Y, Maru D, et al. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. J Clin Oncol 2008; 25:5344-5351.
2. Gómez ML, Vera R, Ortega L, et al. Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy. Clin Transl Oncol 2014; 16(3):234-42.
3. Zorzi D, Kishi Y, Maru D et al. Effect of extended preoperative chemotherapy on pathologic response and postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
4. Ribero D, Wang H, Donadon M et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007; 2761-2767.
5. Klinger M, Tramandl D, Eipeldauer S, et al. Bevacizumab Improves Pathological Response of Colorectal Cancer Liver Metastases Treated with XELOX/FOLFOX. Annals of Surgical Oncology 2010; 17:2059-2065.